Goodman Advisory Group LLC Has $10.87 Million Stock Position in Royalty Pharma PLC $RPRX

Goodman Advisory Group LLC decreased its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 6.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 281,194 shares of the biopharmaceutical company’s stock after selling 18,113 shares during the period. Royalty Pharma accounts for approximately 2.7% of Goodman Advisory Group LLC’s holdings, making the stock its 10th biggest holding. Goodman Advisory Group LLC’s holdings in Royalty Pharma were worth $10,865,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Lloyd Advisory Services LLC. bought a new position in Royalty Pharma during the fourth quarter valued at $30,000. Smartleaf Asset Management LLC grew its stake in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 790 shares in the last quarter. Private Trust Co. NA grew its stake in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 288 shares in the last quarter. Larson Financial Group LLC grew its stake in Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares in the last quarter. Finally, Fifth Third Bancorp grew its stake in Royalty Pharma by 16.9% in the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 362 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

RPRX stock opened at $54.52 on Thursday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The business has a 50-day moving average price of $51.32 and a 200 day moving average price of $45.39. The company has a market capitalization of $31.39 billion, a P/E ratio of 37.09, a PEG ratio of 1.53 and a beta of 0.43. Royalty Pharma PLC has a 1-year low of $33.59 and a 1-year high of $56.50.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.08. The firm had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. As a group, equities research analysts forecast that Royalty Pharma PLC will post 5.05 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were given a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend was Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is 63.95%.

Analysts Set New Price Targets

A number of equities analysts have commented on RPRX shares. UBS Group upped their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, April 21st. Morgan Stanley upped their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Weiss Ratings downgraded shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. JPMorgan Chase & Co. upped their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Citigroup lifted their price objective on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Royalty Pharma has a consensus rating of “Buy” and a consensus target price of $53.71.

Insider Buying and Selling at Royalty Pharma

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total transaction of $161,385.00. Following the sale, the director owned 191,803 shares of the company’s stock, valued at approximately $10,165,559. This trade represents a 1.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $52.75, for a total value of $721,831.00. Following the sale, the executive vice president directly owned 18,197 shares in the company, valued at $959,891.75. This trade represents a 42.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 199,185 shares of company stock valued at $10,082,926. 18.84% of the stock is currently owned by corporate insiders.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.